Comparing Innovation Spending: Exelixis, Inc. and Galapagos NV

Biotech Giants' R&D Spending: A Decade of Innovation

__timestamp	Exelixis, Inc.	Galapagos NV
Wednesday, January 1, 2014	189101000	111110000
Thursday, January 1, 2015	96351000	129714000
Friday, January 1, 2016	95967000	139574000
Sunday, January 1, 2017	112171000	218502000
Monday, January 1, 2018	182257000	322876000
Tuesday, January 1, 2019	336964000	427320000
Wednesday, January 1, 2020	547851000	523667000
Friday, January 1, 2021	693716000	491707000
Saturday, January 1, 2022	891813000	515083000
Sunday, January 1, 2023	1044071000	241294000
Monday, January 1, 2024	910408000

Unleashing insights

Innovation Race: Exelixis, Inc. vs. Galapagos NV

In the dynamic world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Exelixis, Inc. and Galapagos NV have been at the forefront of this race. From 2014 to 2023, Exelixis, Inc. has shown a remarkable growth in R&D expenses, increasing by over 450%, peaking in 2023. In contrast, Galapagos NV's R&D spending saw a more modest increase of around 117% during the same period, with a notable dip in 2023.

This divergence highlights Exelixis, Inc.'s aggressive push towards innovation, while Galapagos NV appears to be recalibrating its strategy. The data suggests that Exelixis, Inc. is positioning itself as a leader in biotech innovation, potentially setting the stage for groundbreaking advancements in the years to come.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025